BCM
AUTL

Burrage Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Burrage Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,006
Closed -$134K – 29
2020
Q4 		$134K Hold
15,006
– – 0.1% 25
2020
Q3 		$175K Hold
15,006
– – 0.14% 27
2020
Q2 		$241K Hold
15,006
– – 0.17% 26
2020
Q1 		$84K Buy
15,006
+1,893
+14% +$17.5K 0.08% 31
2019
Q4 		$173K Buy
+13,113
New +$172K 0.12% 28

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Burrage Capital Management's AUTL Position: Q1 2021 in Review

Burrage Capital Management sold out of Autolus Therapeutics (AUTL) in Q1 2021, closing a stake of 15,006 shares — an estimated $134K sold.

Burrage Capital Management first reported a position in AUTL in Q4 2019 and held it in 5 quarters. The position peaked at $241K in Q2 2020. 63 funds tracked by Wall St. Rank hold AUTL as of Q1 2021.

  • Burrage Capital Management reported no remaining Autolus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Burrage Capital Management sold 15,006 Autolus Therapeutics shares in Q1 2021, an estimated $134K.
  • Burrage Capital Management first reported a position in Autolus Therapeutics in Q4 2019 and held it in 5 quarters.
  • Burrage Capital Management's Autolus Therapeutics position peaked at $241K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2021.

Based on Burrage Capital Management's 13F filing for Q1 2021, filed 17 May 2021.